Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Piramal Imaging SA. Stories

2013-11-20 08:29:30

SEOUL, BERLIN, BOSTON and MUMBAI, India, Nov. 20, 2013 /PRNewswire/ -- Ci-Co Healthcare and Piramal Imaging announce the companies have entered into a strategic partnership and exclusive licensing agreement whereby Ci-Co Healthcare will obtain market authorization from the Korean Health Authorities and commercialize the PET amyloid imaging agent florbetaben F18(*)( )in South Korea. Ci-Co Healthcare has assigned the manufacturing and supply of florbetaben F18 to DuChemBio, a...

2013-10-17 08:30:16

BERLIN, BOSTON and MUMBAI, India, Oct. 17, 2013 /PRNewswire/ -- Piramal Imaging announced today that results from four studies evaluating the Company's PET amyloid imaging agent, florbetaben F18(*), will be presented at the 2013 Annual Congress of the European Association of Nuclear Medicine (EANM), which will be held in Lyon, France from October 19-23, 2013. (Logo: http://photos.prnewswire.com/prnh/20130507/NE09018LOGO ) Florbetaben is currently being reviewed by the Food and Drug...

2013-08-19 12:25:16

BOSTON, Aug. 19, 2013 /PRNewswire/ -- Piramal Imaging announced today that the Company has submitted a detailed response to CMS regarding the draft decision to limit Medicare coverage of beta-amyloid PET imaging in dementia and neurodegenerative disease.(1) Piramal Imaging's response, originally submitted on Monday, July 29, 2013, has been posted on CMS' website as part of the public comment process, which was open through August 2, 2013. As of August 8, 2013, CMS' website indicated...

2013-07-25 12:27:53

Piramal Imaging Urges Public Participation During the CMS Public Comment Period on the use of Beta-Amyloid Imaging in Dementia BERLIN, BOSTON and MUMBAI, India, July 25, 2013 /PRNewswire/ -- On Wednesday, July 3, 2013, the Centers for Medicare & Medicaid Services (CMS) released its proposed decision memorandum regarding the use of beta-amyloid imaging in dementia and neurodegenerative disease.(1) Piramal Imaging is concerned about CMS' proposal, which appears to take an...

2013-07-12 12:25:26

BERLIN, BOSTON and MUMBAI, India, July 12, 2013 /PRNewswire/ -- Piramal Imaging announced today that results from five studies evaluating the Company's PET amyloid imaging agent (florbetaben F18(*)) will be presented at the 2013 Alzheimer's Association International Conference(®) (AAIC 2013) taking place in Boston, Mass. from July 13-18. (Logo: http://photos.prnewswire.com/prnh/20130507/NE09018LOGO ) "These findings continue to reinforce the strength of the florbetaben F18...

2013-06-06 12:28:45

BERLIN, BOSTON and MUMBAI, India, June 6, 2013 /PRNewswire/ -- Piramal Imaging announced today that results from four studies evaluating the Company's PET amyloid imaging agent (florbetaben F18(*)) will be presented at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI 2013) taking place in Vancouver from June 8-12. Additionally, Andrew Stephens, Vice President of Clinical Research and Development at Piramal Imaging will present an update and highlights...

2013-05-07 12:31:35

BERLIN, BOSTON and MUMBAI, India, May 7, 2013 /PRNewswire/ -- Piramal Imaging SA, a division of Piramal Enterprises, today announced Ana M. Catafau, M.D., Ph.D., has joined the company as vice president (VP) of Clinical Research and Development, Neurosciences. (Logo: http://photos.prnewswire.com/prnh/20130507/NE09018LOGO) Dr. Catafau's appointment comes on the heels of Piramal Imaging's announcement that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)...

2012-08-06 02:25:59

DULLES, Va. and MUMBAI, India, Aug. 6, 2012 /PRNewswire/ -- IBA Molecular and Piramal Imaging SA (Piramal) have announced an agreement whereby IBA Molecular will manufacture and distribute 18F-Florbetaben, Piramal's new diagnostic imaging agent, in the European and US markets. 18F- Florbetaben is a radiopharmaceutical currently in development for use with positron emission tomography (PET) for the detection of beta-Amyloid plaque deposition in the brain, a pathological feature associated with...